As targeted therapeutics grow more complex, developers designing bioconjugates face a widening set of scientific and manufacturing variables to coordinate — from conjugation chemistry and linker architecture to payload selection and scale-up planning. To help simplify that process, Xcellon Biologics has launched XSpec™, a proprietary bioconjugation configurator built to streamline early-stage program design for antibody-drug conjugates (ADCs), radioconjugates, imaging agents, and other next-generation targeted therapies.
The online platform lets biotechnology companies, pharmaceutical developers, and research organizations define key program parameters and receive expert scientific feedback before committing to full development.
Structuring a Complex Decision Process
Through the bioconjugation configurator, users can:
- Select optimal conjugate modalities for therapeutic or imaging applications
- Evaluate conjugation chemistries against biological and chemical requirements
- Define linker architecture, payload class, and target Drug-to-Antibody Ratio (DAR)
- Explore advanced strategies, including dual-payload and bioorthogonal approaches
- Specify batch scale and formulation needs
- Build customized analytical and in vitro characterization packages suited to their stage of development
Once a configuration is submitted, Xcellon’s scientific team runs a full feasibility assessment covering chemistry, manufacturability, timelines, and expected deliverables — with initial engagement from a scientist typically within 48 hours.
From Concept to Development
Clients working with Xcellon through XSpec™ receive ongoing progress updates, analytical data packages, and technical support throughout execution. Final deliverables include fully characterized conjugates along with supporting documentation such as Certificates of Analysis (CoA), DAR distribution data, and SEC/HIC chromatograms.
The launch reflects Xcellon’s broader focus as a Contract Research, Development, and Manufacturing Organization (CRDMO) built specifically for the bioconjugation sector — supporting every stage from linker-payload design and site-specific conjugation through analytical characterization and manufacturing readiness.
Learn more or start a project with our new platform.
Originally covered by BioBuzz, June 3, 2026.
